Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. The last earnings update was 6 days ago. More info.
Add to Portfolio Compare Print
- Zealand Pharma has significant price volatility in the past 3 months.
ZEAL Share Price and Events
7 Day Returns
1 Year Returns
ZEAL Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Zealand Pharma (ZEAL) | 8.4% | 22.1% | 55.6% | 46.9% | 13% | 132.3% |
| DK Biotechs | 6.8% | 6.8% | 17.7% | -3.5% | -5.6% | 318.5% |
| DK Market | 1.2% | -0.7% | 1.6% | -0.6% | 3.1% | 35.7% |
1 Year Return vs Industry and Market
- ZEAL outperformed the Biotechs industry which returned -3.5% over the past year.
- ZEAL outperformed the Market in Denmark which returned -0.6% over the past year.
ZEAL Value
Is Zealand Pharma undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Zealand Pharma. This is due to cash flow or dividend data being unavailable. The share price is DKK147.5.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Zealand Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Zealand Pharma's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in DKK | DKK17.93 |
| CPSE:ZEAL Share Price ** | CPSE (2019-05-22) in DKK | DKK147.5 |
| Europe Biotechs Industry PE Ratio | Median Figure of 29 Publicly-Listed Biotechs Companies | 20.63x |
| Denmark Market PE Ratio | Median Figure of 103 Publicly-Listed Companies | 16.22x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Zealand Pharma.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = CPSE:ZEAL Share Price ÷ EPS (both in DKK) = 147.5 ÷ 17.93 |
8.22x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Zealand Pharma is good value based on earnings compared to the Europe Biotechs industry average.
- Zealand Pharma is good value based on earnings compared to the Denmark market.
Price based on expected Growth
Does
Zealand Pharma's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 8.22x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts |
6.2%per year |
| Europe Biotechs Industry PEG Ratio | Median Figure of 23 Publicly-Listed Biotechs Companies | 1.25x |
| Denmark Market PEG Ratio | Median Figure of 44 Publicly-Listed Companies | 2.14x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 8.22x ÷ 6.2% |
1.33x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Zealand Pharma is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on
Zealand Pharma's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in DKK | DKK35.12 |
| CPSE:ZEAL Share Price * | CPSE (2019-05-22) in DKK | DKK147.5 |
| Denmark Biotechs Industry PB Ratio | Median Figure of 6 Publicly-Listed Biotechs Companies | 3.37x |
| Denmark Market PB Ratio | Median Figure of 135 Publicly-Listed Companies | 1.64x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = CPSE:ZEAL Share Price ÷ Book Value per Share (both in DKK) = 147.5 ÷ 35.12 |
4.2x |
* Primary Listing of Zealand Pharma.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Zealand Pharma is overvalued based on assets compared to the DK Biotechs industry average.
Value checks
We assess Zealand Pharma's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Zealand Pharma has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
ZEAL Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Zealand Pharma's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
- Zealand Pharma's earnings growth is positive but not above the Denmark market average.
- Zealand Pharma's revenue growth is expected to exceed the Denmark market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| CPSE:ZEAL Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts | 6.2% |
| CPSE:ZEAL Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts | 22.9% |
| Denmark Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 23.5% |
| Europe Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 14.3% |
| Denmark Market Earnings Growth Rate | Market Cap Weighted Average | 11.8% |
| Denmark Market Revenue Growth Rate | Market Cap Weighted Average | 6.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| Date (Data in DKK Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 381 | -348 | 7 | 3 |
| 2022-12-31 | 200 | -442 | -344 | 3 |
| 2021-12-31 | 173 | -301 | -300 | 5 |
| 2020-12-31 | 183 | -361 | -363 | 6 |
| 2019-12-31 | 167 | -295 | -353 | 6 |
| Date (Data in DKK Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 28 | -319 | 551 |
| 2018-12-31 | 38 | -460 | 581 |
| 2018-09-30 | 39 | -417 | 597 |
| 2018-06-30 | 78 | -310 | -370 |
| 2018-03-31 | 72 | -320 | -338 |
| 2017-12-31 | 136 | -279 | -275 |
| 2017-09-30 | 306 | -64 | -112 |
| 2017-06-30 | 307 | -113 | -100 |
| 2017-03-31 | 306 | -52 | -102 |
| 2016-12-31 | 231 | 41 | -157 |
| 2016-09-30 | 221 | -114 | -138 |
| 2016-06-30 | 189 | -128 | -158 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
All data from Zealand Pharma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in DKK Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | -11.80 | -11.80 | -11.80 | 1.00 |
| 2022-12-31 | -14.80 | -14.80 | -14.80 | 1.00 |
| 2021-12-31 | -10.36 | -8.20 | -12.72 | 3.00 |
| 2020-12-31 | -10.51 | -8.20 | -13.30 | 5.00 |
| 2019-12-31 | -10.35 | -8.60 | -11.20 | 4.00 |
| Date (Data in DKK Millions) | EPS * |
|---|---|
| 2019-03-31 | 17.93 |
| 2018-12-31 | 18.94 |
| 2018-09-30 | 19.23 |
| 2018-06-30 | -12.18 |
| 2018-03-31 | -11.61 |
| 2017-12-31 | -9.88 |
| 2017-09-30 | -4.26 |
| 2017-06-30 | -3.96 |
| 2017-03-31 | -4.14 |
| 2016-12-31 | -6.47 |
| 2016-09-30 | -5.78 |
| 2016-06-30 | -6.69 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Zealand Pharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Future performance checks
We assess Zealand Pharma's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Denmark market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Zealand Pharma has a total score of 3/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
ZEAL Past Performance
How has Zealand Pharma performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Zealand Pharma has delivered over 20% year on year earnings growth in the past 5 years.
- Zealand Pharma has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
- Zealand Pharma has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
All data from Zealand Pharma Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in DKK Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 28.26 | 551.13 | 56.69 | 464.09 |
| 2018-12-31 | 37.98 | 581.28 | 50.24 | 431.52 |
| 2018-09-30 | 38.83 | 596.59 | 52.73 | 397.83 |
| 2018-06-30 | 77.92 | -370.32 | 51.50 | 382.59 |
| 2018-03-31 | 71.88 | -338.31 | 49.92 | 343.57 |
| 2017-12-31 | 136.32 | -275.26 | 53.57 | 318.57 |
| 2017-09-30 | 306.31 | -111.86 | 57.86 | 292.88 |
| 2017-06-30 | 306.80 | -99.64 | 55.13 | 274.25 |
| 2017-03-31 | 305.66 | -102.43 | 60.97 | 259.10 |
| 2016-12-31 | 230.86 | -157.30 | 58.60 | 262.06 |
| 2016-09-30 | 221.38 | -137.86 | 51.26 | 243.16 |
| 2016-06-30 | 189.02 | -157.94 | 55.03 | 237.42 |
| 2016-03-31 | 188.38 | -138.53 | 47.86 | 223.60 |
| 2015-12-31 | 187.68 | -113.96 | 47.82 | 211.74 |
| 2015-09-30 | 26.87 | -245.71 | 47.55 | 217.05 |
| 2015-06-30 | 77.82 | -177.87 | 44.32 | 212.27 |
| 2015-03-31 | 74.82 | -147.07 | 39.33 | 194.90 |
| 2014-12-31 | 153.77 | -64.99 | 39.83 | 180.04 |
| 2014-09-30 | 150.65 | -46.80 | 31.24 | 160.24 |
| 2014-06-30 | 94.79 | -98.25 | 32.97 | 150.74 |
| 2014-03-31 | 91.57 | -97.50 | 35.09 | 147.14 |
| 2013-12-31 | 6.57 | -183.68 | 34.16 | 164.47 |
| 2013-09-30 | 3.40 | -191.37 | 33.93 | 177.37 |
| 2013-06-30 | 38.45 | -157.36 | 32.91 | 186.25 |
| 2013-03-31 | 103.28 | -86.64 | 28.61 | 194.83 |
| 2012-12-31 | 223.57 | 36.37 | 27.61 | 182.76 |
| 2012-09-30 | 245.88 | 69.67 | 26.76 | 169.47 |
| 2012-06-30 | 209.18 | 55.94 | 28.14 | 148.43 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Zealand Pharma made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
- Zealand Pharma used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
- Zealand Pharma has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
Past performance checks
We assess Zealand Pharma's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Zealand Pharma has a total score of 4/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
ZEAL Health
How is Zealand Pharma's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Zealand Pharma's finances.
The net worth of a company is the difference between its assets and liabilities.
- Zealand Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Zealand Pharma has no long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 217.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Zealand Pharma Company Filings, last reported 1 month ago.
| Date (Data in DKK Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 1,084.29 | 5.95 | 1,263.31 |
| 2018-12-31 | 1,116.28 | 0.00 | 1,159.25 |
| 2018-09-30 | 1,240.77 | 0.00 | 1,478.61 |
| 2018-06-30 | 316.24 | 143.44 | 461.34 |
| 2018-03-31 | 437.06 | 134.15 | 561.10 |
| 2017-12-31 | 514.67 | 135.73 | 663.83 |
| 2017-09-30 | 638.98 | 141.90 | 774.65 |
| 2017-06-30 | 181.53 | 146.05 | 302.11 |
| 2017-03-31 | 252.69 | 161.49 | 410.27 |
| 2016-12-31 | 278.19 | 332.24 | 323.33 |
| 2016-09-30 | 217.63 | 312.15 | 224.64 |
| 2016-06-30 | 107.52 | 311.22 | 289.36 |
| 2016-03-31 | 178.64 | 301.93 | 358.76 |
| 2015-12-31 | 252.23 | 312.95 | 418.80 |
| 2015-09-30 | 159.43 | 333.23 | 453.89 |
| 2015-06-30 | 163.04 | 301.12 | 468.61 |
| 2015-03-31 | 209.18 | 308.69 | 523.98 |
| 2014-12-31 | 252.83 | 272.17 | 516.85 |
| 2014-09-30 | 316.22 | 0.00 | 303.81 |
| 2014-06-30 | 299.36 | 0.00 | 297.62 |
| 2014-03-31 | 344.99 | 0.00 | 349.65 |
| 2013-12-31 | 316.14 | 0.00 | 310.56 |
| 2013-09-30 | 361.90 | 0.00 | 357.83 |
| 2013-06-30 | 396.03 | 0.00 | 403.58 |
| 2013-03-31 | 442.55 | 0.00 | 441.30 |
| 2012-12-31 | 491.02 | 0.00 | 485.79 |
| 2012-09-30 | 536.66 | 0.00 | 498.33 |
| 2012-06-30 | 536.79 | 0.00 | 524.96 |
- Zealand Pharma's level of debt (0.5%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (0% vs 0.5% today).
- Operating cash flow is negative therefore debt is not well covered.
- Interest payments on debt are well covered by earnings (EBIT is 36.5x coverage).
Financial health checks
We assess Zealand Pharma's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Zealand Pharma has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
ZEAL Dividends
What is Zealand Pharma's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
DKK2,000 of
Zealand Pharma
shares you are expected to receive
DKK0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Zealand Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Zealand Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| Europe Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 9 Stocks | 0.8% |
| Denmark Market Average Dividend Yield | Market Cap Weighted Average of 78 Stocks | 2.5% |
| Denmark Minimum Threshold Dividend Yield | 10th Percentile | 1% |
| Denmark Bottom 25% Dividend Yield | 25th Percentile | 1.6% |
| Denmark Top 25% Dividend Yield | 75th Percentile | 4.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in DKK) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | 0.00 | 1.00 |
| 2019-12-31 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Zealand Pharma has not reported any payouts.
- Unable to verify if Zealand Pharma's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Zealand Pharma's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Zealand Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Zealand Pharma has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
ZEAL Management
CEO
| AGE | 48 |
| TENURE AS CEO | 0.1 years |
CEO Bio
Dr. Emmanuel Dulac, PharmD, PhD, MBA, has been Chief Executive Officer at Zealand Pharma A/S since April 22, 2019 and its President since 2019. He had been Chief Commercial Officer and Senior Vice President of Alnylam Pharmaceuticals, Inc. from September 19, 2016 to June 2018 and its Chief International Strategy since August 2016. Dr. Dulac has more than 20 years of international experience in the biotech and pharmaceutical industry. He joined Alnylam Pharmaceuticals, from Shire, where he was Senior Vice President, Global Head of the Rare Disease Business Unit and General Manager of United States Operations from June 2014 to August 2016. Dr. Dulac held several leadership roles of increasing responsibility at Novartis (NYSE:NVS) from February 2006 to May 2014, including Vice President, Global Head Lung/Cystic Fibrosis. From August 2003 to February 2006, he was Business Unit Lead for Cardiovascular Medicine at Abbott (NYSE:ABT). Dr. Dulac held several roles of increasing responsibility at Sanofi (NASDAQ:SNY) from October 1994 to August 2003, including Associate Director. During his career, he successfully launched six brands, led two blockbuster drugs globally and built large sales organizations, innovative patient services and strong marketing and market access teams. He has been a Director of Proteostasis Therapeutics, Inc. since February 5, 2019. He graduated from the University of Paris XI with a Doctorate in Pharmacology (PharmD, Ph.D.) and completed an MBA from the ESSEC School in Paris.
CEO Compensation
- Insufficient data for Emmanuel to compare compensation growth.
- Insufficient data for Emmanuel to establish whether their remuneration is reasonable compared to companies of similar size in Denmark.
Management Team Tenure
Average tenure and age of the Zealand Pharma management team in years:
- The average tenure for the Zealand Pharma management team is less than 2 years, this suggests a new team.
Management Team
Hanne Bak
Senior Project Director
DKK300K
65
5.1 yrs
Emmanuel Dulac
CEO & President
48
0.1 yrs
Ivan Møller
Interim CFO and Senior VP of Technical Development & Operations
46
Andy Parker
Executive VP & Chief Science Officer
53
2.8 yrs
Lani Morvan
Investor Relations & Communications Officer
Søren Keller
Head of Legal Affairs
5.1 yrs
Marino Garcia
Senior Vice President of Corporate & Business Development
52
0.6 yrs
Niels Mørk
Head of Bioanalysis
Jens Mikkelsen
Head of Molecular Pharmacology
Adam Steensberg
Executive VP and Chief Medical & Development Officer
44
0.3 yrs
Board of Directors Tenure
Average tenure and age of the Zealand Pharma board of directors in years:
- The tenure for the Zealand Pharma board of directors is about average.
Board of Directors
Martin Nicklasson
Chairman of the Board
DKK750K
63
4.1 yrs
Kirsten Drejer
Vice Chairman
DKK200K
62
0.1 yrs
Hanne Bak
Senior Project Director
DKK300K
65
3.1 yrs
Alain Munoz
Co-Chair of the Clinical & Scientific Advisory Board & Director
DKK350K
69
7.5 yrs
Leon Kruimer
Director
60
0.1 yrs
Tyge Korsgaard
Board Observer
Bernard Charbonnel
Member of Advisory Board
7.5 yrs
Richard Pratley
Member of Advisory Board
7.5 yrs
Paul Dorian
Member of Advisory Board
7.5 yrs
Ake Lernmark
Member of Advisory Board
73
7.5 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (DKK) | Value (DKK) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Zealand Pharma's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Zealand Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
ZEAL News
Simply Wall St News
Is Zealand Pharma A/S's (CPH:ZEAL) 48% Better Than Average?
With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Our data shows Zealand Pharma has a return on equity of 48% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleShould You Be Concerned About Zealand Pharma A/S's (CPH:ZEAL) Investors?
In this article, I'm going to take a look at Zealand Pharma A/S’s (CPH:ZEAL) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … The impact of a company's ownership structure affects both its short- and long-term performance. … See our latest analysis for Zealand Pharma
Simply Wall St - – Full articleZealand Pharma A/S's (CPH:ZEAL) Path To Profitability
Zealand Pharma A/S's (CPH:ZEAL):. … Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. … The ø2.90b market-cap posted a loss in its most recent financial year of -ø272.27m and a latest trailing-twelve-month loss of -ø337.35m leading to an even wider gap between loss and breakeven?
Simply Wall St - – Full articleWhat Are Analysts Saying About The Future Of Zealand Pharma A/S's (CPH:ZEAL)?
Zealand Pharma A/S's (CPSE:ZEAL) released its most recent earnings update in December 2017, which confirmed company earnings became less negative compared to the previous year's level - great news for investors Below, I've laid out key numbers on how market analysts predict Zealand Pharma's earnings growth outlook over the next couple of years and whether the future looks brighter. … See our latest analysis for Zealand Pharma Analysts' outlook for this coming year seems pessimistic, with earnings becoming even more negative, arriving at -Ø389.33M in 2019. … Future Earnings: How does ZEAL's growth rate compare to its peers and the wider market?
Simply Wall St - – Full articleZealand Pharma A/S (CPH:ZEAL): When Will It Breakeven?
Many investors are wondering the rate at which ZEAL will turn a profit, with the big question being “when will the company breakeven?” I’ve put together a brief outline of industry analyst expectations for ZEAL, its year of breakeven and its implied growth rate. … See our latest analysis for Zealand Pharma Expectation from analysts is ZEAL is on the verge of breakeven. … How fast will ZEAL have to grow each year in order to reach the breakeven point by 2022?
Simply Wall St - – Full articleAnalysts Bearish On Zealand Pharma A/S (CPH:ZEAL)
Given its debt level is relatively minimal (-205.36% of equity), the fact that ZEAL's cash only covers a mere -205.36% of debt makes me uneasy. … There's room for improvement on the cash management side of things, but its overall debt level and interest coverage somewhat increases my conviction of the sustainability of the business going forward. … One reason I do like ZEAL as a business is its low level of fixed assets on its balance sheet (2.19% of total assets).
Simply Wall St - – Full articleShould You Be Concerned With Zealand Pharma A/S's (CPH:ZEAL) -76.90% Earnings Drop?
Measuring Zealand Pharma A/S's (CPSE:ZEAL) track record of past performance is a useful exercise for investors. … See our latest analysis for Zealand Pharma How Did ZEAL's Recent Performance Stack Up Against Its Past? … For Zealand Pharma, its latest earnings (trailing twelve month) is -Ø272.27M, which, against the prior year's figure, has become more negative.
Simply Wall St - – Full articleZEAL Company Info
Description
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company’s product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH; and Alexion Pharmaceuticals, Inc. for the discovery and development of peptide therapies for complement-mediated diseases. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
Details
| Name: | Zealand Pharma A/S |
| ZEAL | |
| Exchange: | CPSE |
| Founded: | 1997 |
| DKK4,663,317,667 | |
| 31,615,713 | |
| Website: | http://www.zealandpharma.com |
| Address: |
Zealand Pharma A/S Smedeland 36, Glostrup, Copenhagen, Capital Region of Denmark, 2600, Denmark |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| CPSE | ZEAL | Ordinary Shares | OMX Nordic Exchange Copenhagen | DK | DKK | 23. Nov 2010 | |
| OTCPK | ZLDP.F | Ordinary Shares | Pink Sheets LLC | US | USD | 23. Nov 2010 | |
| DB | 22Z | Ordinary Shares | Deutsche Boerse AG | DE | EUR | 23. Nov 2010 | |
| LSE | 0NZU | Ordinary Shares | London Stock Exchange | GB | DKK | 23. Nov 2010 | |
| BATS-CHIXE | ZEALC | Ordinary Shares | BATS 'Chi-X Europe' | GB | DKK | 23. Nov 2010 | |
| NasdaqGS | ZEAL | SPONSORED ADR | Nasdaq Global Select | US | USD | 09. Aug 2017 | |
| DB | 22ZA | SPONSORED ADR | Deutsche Boerse AG | DE | EUR | 09. Aug 2017 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/22 21:26 |
| End of day share price update: | 2019/05/22 00:00 |
| Last estimates confirmation: | 2019/05/21 |
| Last earnings filing: | 2019/05/16 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
